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Abstract
Background: In contrast to typical measures employed to assess outcomes in healthcare such as mortality or
recovery rates, it is difficult to define which specific outcomes of care are the most important in caring for dying
individuals. Despite a variety of tools employed to assess different dimensions of palliative care, there is no
consensus on a set of core outcomes to be measured in the last days of life.
In order to optimise decision making in clinical practice and comparability of interventional studies, we aim to
identify and propose a set of core outcomes for the care of the dying person.
Methods: Following the COMET initiative approach, the proposed study will proceed through four stages to
develop a set of core outcomes: In stage 1, a systematic review of the literature will identify outcomes measured in
existing peer reviewed literature, as well as outcomes derived through qualitative studies. Grey literature, will also
be included. Stage 2 will allow for the identification and determination of patient and proxy defined outcomes of
care at the end of life via quantitative and qualitative methods at an international level. In stage 3, from a list of
salient outcomes identified through stages 1 and 2, international experts, family members, patients, and patient
advocates will be asked to score the importance of the preselected outcomes through a Delphi process. Stage 4
consists of a face-to-face consensus meeting of international experts and patient/family representatives in order to
define, endorse, and propose the final Core Outcomes Set.
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Discussion: Core Outcome Sets aim at promoting uniform assessment of care outcomes in clinical practice as well
as research. If consistently employed, a robust set of core outcomes for the end of life, and specifically for the dying
phase, defined by relevant stakeholders, can ultimately be translated into best care for the dying person. Patient
care will be improved by allowing clinicians to choose effective and meaningful treatments, and research impact
will be improved by employing internationally agreed clinically relevant endpoints and enabling accurate
comparison between studies in systematic reviews and/or in meta-analyses.
Keywords: Core outcomes set, Outcomes, Outcomes research, Delphi study, Palliative care, Last days of life, End of
life
Background
In contrast to the typical measures employed to assess
healthcare outcomes such as mortality or recovery rates,
difficulties exist in defining which specific outcomes of
care are the most important when caring for dying indi-
viduals. In the last phase of life, a variety of dimensions
of care have been found to be important, such as symp-
tom control, whole person care, quality of death and
dying, and a good death [1]. A focus on these constructs
as care outcomes has led to the development of inter-
ventions and measures that ensure that these standards
are met, thus improving care at the end of life [2].
A main limitation of outcomes research in palliative
care is that the focus of most interventions or tools
assessing goals, outcomes, and quality of care has been
about end-of-life care or palliative care in general, and
not for the last days of life. While some efforts have been
made to specify distinct stages of palliative care: early
palliative care, end of life care, and care of the dying,
and assign to them a specific timeframe, no standardised
definition/timeframe exists [3–5]. Yet, the last days of
life, or ‘care of the dying’, is considered as a discrete
phase of palliative care [6]. The identification and under-
standing of needs and concerns in the last days of life is
important to inform patient care because as patients’
health status changes, e.g. due to an acute deterioration,
they may become more aware of their impending death,
and change their own goals of care (such as those identi-
fied in Advance Care Planning).
Similarly, another limitation of research focusing on
outcomes of care is that it has been often produced from
the perspective of health professionals and academics
[7]. Patients and families have been given less opportun-
ities to define which outcomes are of importance to
them. With their medical background, health profes-
sionals may give more relevance to medical aspects of
care, while for the patient, there may be other pressing
issues [7]. As an example, of the many areas integral to
the provision of palliative care, the majority of measures
have been found to over-represent physical symptoms,
and to fail to address the care needs of the imminently
dying patient in cancer and non-malignant advanced ill-
nesses [6, 8, 9].
Questions regarding patient priorities as to which out-
comes of care are more relevant in the last days of life
remain relatively unexplored, or lacking direct assess-
ment of patients in the last days of life [10]. Given that
so many patients access palliative care at a late stage,
and many other patients never receive palliative care
[11], how can services best identify and meet the needs
and goals of dying people, and how can they effectively
measure them? There is a pressing need to undertake re-
search with a more narrow focus into this stage [12].
During the last days of life, the symptoms of dying, as
well as the illness itself and the awareness of dying may
affect the patient at a level in which it had not before,
and many areas of patient and family need could be
neglected, or given less importance based on current
outcome standards [13]. What has been overlooked is
the possibility that the patients’ wishes may evolve dur-
ing the course of the illness and the treatment offered
during the last days of life may not be in line with their
wishes. Capturing patient preferences at the right time
also has the potential to produce meaningful results that
will be of relevance to their own needs: “the issues that
are important to the dying are not likely to be the same
at all stages of their illness: the problems of patients very
close to death need to be dealt with on the basis of evi-
dence obtained in patients very close to death” [14].
With the shift towards patient autonomy and person-
centred care, the patient perspective has become a pre-
dominant voice in the assessment of the quality of care,
and more importantly, in the establishment of goals and
outcomes of care [7, 15–17]. Outcomes research is lead-
ing health care professionals to recognize that it is the
patient who determines the success of medical treat-
ments, both when measuring outcomes and when defin-
ing them [15, 18–20]. While patient-centred outcomes
have traditionally been of importance in palliative care
research and education, the patient perspective in the
definition of outcomes has been less studied, leading re-
searchers to question themselves on whether current
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models of service delivery and research agendas do re-
flect patient priorities [13].
Originally intended for the measurement of the effects
of specific interventions in clinical trials, core outcomes
of care are increasingly being employed outside the re-
search context to ensure that patient care is relevant and
so that it can be efficiently measured and compared
across services [17].
In palliative care, outcomes research has gained an im-
portant role in defining the need, value, and quality of
care at the end of life [20]. However, outcome hetero-
geneity has been identified as one of the reasons why
palliative care research has failed to inform clinical prac-
tice [21–23]. National registries of palliative care out-
comes have been implemented in many countries as a
quality improvement strategy. Among these, the Swedish
Palliative Care Registry is one of the few to include mea-
sures of the quality of care relevant to the last week of
life [24].
To date, despite efforts to harmonise how palliative
care outcomes should be measured (i.e. through which
tools or instruments) [25], no international consensus
process has been undertaken to determine what the
main outcomes of care are, (i.e. what dimensions should
be addressed as the outcomes of care) particularly for
the last days of life and including the patient perspective.
Development of a Core outcome set (COS) for the last
days of life
The Core Outcome Measures in Effectiveness Trials
(COMET), an international initiative initially funded
within the European Commission 7th Framework
Programme, became a main advocate of outcome stand-
ardisation through the development of Core Outcome
Sets. A COS represents a consensually predefined mini-
mum of important outcomes that should be measured in
a specific context. COS are increasingly being developed
and implemented in several areas to ensure comparabil-
ity across studies and clinical services, and to reduce re-
search waste due to outcome heterogeneity [26, 27].
While there is an expectation and motivation to employ
them as a predefined minimum in all trials and also to
compare quality of care across clinical services, their
utilisation does not restrict the inclusion of other out-
comes that may be of interest and which may not be
part of the minimum; in fact, as long as they are in-
cluded, outcomes in a COS do not need to be a primary
outcome [28]. This means that researchers will not have
to exclude outcomes of their own interest, but that by
employing the COS, the findings of their research will
have a greater impact.
The COMET initiative centralises a registry of COS
development studies to increase collaboration between
researchers and to avoid duplication of COS. On their
website, there are no groups focusing on COS develop-
ment for palliative care in general, nor for the last days
of life. Of the registered studies relevant to palliative
care, one is a systematic review describing the range
and quality of outcome measures in care homes [29],
and another one is a position paper about the need to
harmonise outcome measures in palliative care [30].
The only COS development projects in palliative care
are focused on: family bereavement following an illness
[31], treatment of psychological distress for family care-
givers of patients with cancer or in palliative care [32],
outcomes for lung cancer [33], COS measures for colo-
rectal cancer [34], and a COS for the prevention of de-
lirium [35].
Scope of the COS
This project is embedded as a Work Package into a lar-
ger project funded by the European Union’s Horizon
2020 research and innovation programme, entitled
iLIVE, which follows the research activities of the Inter-
national Collaborative for Best Care for the Dying
Person (derived from the former OPCARE 9 project, EU
7th Framework). This will be the first study to investi-
gate and define what the core outcomes for the last days
of life are, and to include in the consensus process the
perspective of families, patient representatives, and other
key stakeholders. Taking into consideration that within
palliative care the family and the patient form the unit of
care [36] and that outcomes of the last days of life im-
pact family wellbeing after death, the COS will be devel-
oped to include outcomes relevant to the patient and
the family. Although most COS focus on outcomes rele-
vant to patients only, examples of COS including two
target groups exist. For example, a COS for the preven-
tion of preterm birth endorsed a final COS that included
items for the pregnant women, as well as outcomes fo-
cused on the offspring [37].
This project aims to identify and propose a set of core
outcomes for best care for the dying person, where
dying is understood as the point at which individuals
are clinically recognised to have entered the dying
phase and may thus have only hours or days to live, in-
dependent of their diagnosis, grounded in a systematic
review of the literature and determined through the
perspective of patients, family members, researchers,
and health professionals. The COS is intended to be
used for research purposes, as well as in clinical prac-
tice, that is, it will optimise both decision making in
clinical practice, as well as improve the comparability
of interventional studies. The COS is expected to be
relevant in all settings where an individual may be
cared for at the end of life: at home, in the hospital, in
hospices, or in other facilities.
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Methods/design
The study will follow the approach suggested by the
COMET (Core Outcome Measures in Effectiveness
Trials) initiative [38, 39] and will adhere to the COS-
STAD recommendations for COS development [40].
The development of COS involves four stages: 1) a sys-
tematic review to identify currently employed outcomes,
2) studies to identify the patient and family perspective,
3) a Delphi study to prioritise outcomes derived from
stages 1 and 2, and 4) a face-to-face consensus meeting
to agree and endorse the final COS (see Fig. 1). Through
this process we will define what are the important out-
comes of care for the last days of life. Recommendations
on how to assess the outcomes will be provided on the
basis of the systematic review, as well as through existing
recommendations such as those developed by MORE-
care [25]. The COS development study has been
registered on the COMET database (http://www.comet-
initiative.org/studies/details/967).
Stage 1: systematic review
A systematic review is one of the main steps in the iden-
tification of existing outcomes. The review aims to
summarize what outcomes are systematically measured
at the end of life, how are they assessed, that is, through
which specific tools, when are they assessed, who reports
on the outcome: whether the patient, the family or the
health professionals, and which of these outcomes would
be relevant for the last days of life.
Definitions
For the purpose of the systematic review, we need to
predefine two central concepts: outcomes, and end of life.
Considering the specific features and domains of pallia-
tive care, outcomes will be understood as the effect or
the end result of a given treatment/intervention on the
patient, the family of the patient, the medical services, or
on the health system. Although the COS will focus on
patient and family outcomes, the review will take into
account all other outcomes assessed in the studies to be
included. Outcomes to be extracted from the studies will
include not only those strictly denoted as ‘outcomes’ or
‘endpoints’, but particularly in the observational studies,
they will be identified in terms of specific areas of inter-
est such as: ‘satisfaction with care’, ‘quality indicators;
e.g. ‘quality of life’, ‘quality of end of life’, ‘quality of
death and dying’, ‘perceptions’, ‘standards’, ‘goals of care’,
‘end of life wishes’, or ‘factors considered important in
the last days of life’.
Taking into account the lack of a standard definition
or a specific time frame for the term end of life [4, 41]
we will include literature focused on people with incur-
able, advanced illnesses who are considered to be at the
end of life, but with an explicit life expectancy of one
month to days of life, so that the outcomes identified are
as close as possible to the dying phase. To narrow down
the search terms for ‘end of life’ we will include a com-
bination of those employed by the National Institute for
Health and Care Excellence in their development of the
National Guidelines for the Care of Dying Adults in the
Last Days of Life [42]. All outcomes from these studies
will be selected for the long list to be generated for the
Delphi Study (Stage 3). Studies which do not specify or
which involve a variety of periods will not be included
for review.
Types of studies
The review will focus on outcomes which have been
employed in interventional studies, as well as outcomes
identified through other peer-reviewed literature, includ-
ing observational studies, surveys, and qualitative stud-
ies. Grey literature, patient registries, and relevant
national guidelines or quality improvement initiatives
from different countries will be searched for and in-
cluded in the analysis when relevant. Outcomes from
ongoing trials registered in the International Clinical
Trials Registry Platform (ICTRP) from the World Health
Organisation [43] (which includes data from at least 17
independent international registries) will be extracted.
The protocol for the systematic review has been
Fig. 1 Study design
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registered prospectively on the PROSPERO database
(registration number pending).
Types of participants/population
This review will consider studies if they include adults
who were at the end of life. However, since the term has
a broad definition of a life expectancy of months to days
of life, we will narrow our selection to include only those
studies reporting no longer than the last month of life.
Studies will be considered if outcomes are defined or re-
ported by patients, health professionals, and/or family
members. Outcomes will be included whether they dir-
ectly affected the patient, the family members, the health
professionals, or the health system as a whole. Studies
undertaken in any setting of care (hospital, hospice,
community, home) will be included.
Condition or domain being studied
The systematic review aims to identify outcomes which
are considered important during the last days of life
from the perspective of patients, family members, clini-
cians, and researchers. The outcomes can be identified
in the context of any chronic illness or condition which
is at an advanced stage such as advanced cancer, end-
stage kidney, lung or heart disease, dementia, etc., and
taking into account the variety of contexts where dying
people can be cared for during the last days and weeks
of life (e.g. home, hospital, hospice, aged care facilities).
Exclusion criteria
Studies will be excluded if they report on end of life as-
pects within paediatrics, on non-human research, or if
they are from the perspective of healthy individuals or
the general population, with the exception of bereaved
family members and health professionals, as long as the
time period considered in the specific study is limited to
the last month of life.
Information sources
Studies will be retrieved from the following electronic
databases: Medline, CINAHL, PsycInfo, and Embase.
Unpublished interventional studies will be identified
from the ICTRP and the Cochrane Central Register of
Controlled Trials. In addition, a manual search of refer-
ences from relevant articles will lead to identifying other
potentially important publications. National guidelines,
statements or standards will be searched for on the
Internet and through a snowballing technique via the
members of the Collaboration for Best Care for the
Dying Person.
Studies in English, Spanish, and German will be con-
sidered for inclusion in the review. The search terms
have been piloted and adapted to the syntax of all
databases and have been uploaded to PROSPERO: Inter-
national prospective register of systematic reviews.
Selection process
Initially, two review team members will screen the first
100 titles and abstracts independently and will compare
their results. After checking for disagreements, titles and
abstracts of all articles identified through the searches
will continue to be screened independently by at least
two researchers who will be blinded to each other’s deci-
sions. In this initial screening process, duplicates will be
discarded and each study will be categorized as: a) to be
included, b) to be discarded, or c) unsure. A similar pro-
cedure will be followed with all excluded articles after
full-text review. Full-texts of all potentially relevant arti-
cles, which fell in the ‘to be included’ or the ‘unsure’ cat-
egories, will be obtained and will be assessed according
to the inclusion criteria. The process of article selection
will be shown in a PRISMA flow diagram and the review
will adhere to the PRISMA reporting guidelines [44].
At all stages, disagreements will be resolved through
discussions until consensus is reached, and if there is no
agreement between the reviewers a third party will be
involved.
Data extraction process
From each included study a minimum of information
will be extracted through a data extraction tool. The tool
will be piloted and refined with an initial set of articles.
Risk of bias in individual studies
Since the main goal of the systematic review is to aid in
the generation of the initial list of outcomes, the risk of
bias of each of the studies, as well as the quality of each
of the studies will not be assessed.
Strategy for data synthesis
A narrative synthesis of the findings of the review will be
structured around the types of outcomes measured, the
tools employed to measure these outcomes, the charac-
teristics of the target population, and type of interven-
tion (if it is an interventional study). If enough data are
available, a subgroup narrative synthesis of differences
between cancer and non-cancer patients, within non-
malignant illnesses, differences according to age groups,
place of care, and place of death will be made.
Selection of outcomes for Delphi study
Once outcomes have been identified, each individual
outcome will be grouped into greater outcome domains.
The taxonomy developed by COMET [45] will be
employed. Depending on the length of the list, the out-
comes will be grouped by frequency of use across the
reviewed studies. A differentiation will be made between
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the outcomes identified in the interventional studies
(most likely to be researcher-defined), and those arising
from other types of studies (most likely to be
participant-defined –that is from the user perspective).
Stage 2: definition of patient and proxy defined
outcomes
A second stage will determine patient and proxy defined
outcomes of care important to the last days of life.
Within the iLIVE project, data on outcomes relevant
to patients and families will be collected prospectively,
and longitudinally, as part of a cohort study in 11
countries (Netherlands, UK, Germany, Sweden,
Slovenia, Switzerland, Spain, Norway, Iceland, New
Zealand, and Argentina). A separate protocol will de-
scribe this part of the study.
Studies about patient and proxy defined outcomes
may also be duplicated in several countries, under the
lead of members of the International Collaborative for
Best Care for the Dying Person. The aim of these studies
will be to define, from the perspective of the patients
and bereaved relatives, what are the aspects and goals of
care which are most relevant in the last days of life. In
addition, outcomes from ongoing or prior studies under-
taken by members of the collaborative, in which infor-
mation about patient and proxy perspectives on
outcomes relevant to the last days of life exists, will be
included into the outcome list. Any potential ethical is-
sues of re-analysing data collected for different purposes
will be resolved before accessing the data (e.g. by anon-
ymising datasets or seeking new ethical approvals).
The methodologies for studies to be included within
this stage, outside of data collected through iLIVE, will
be varied, e.g. in-depth interviews - particularly with
family members, surveys, q-sort cards, or prospectively
collected clinical data about expectations, goals and
wishes of patients and family members. The specific
methods will be chosen by each institution taking into
account feasibility in each of the contexts/countries
where the studies will be performed. Although having a
variety of methods and sample sizes may be seen as
compromising research rigour, since the outcomes to be
extracted from these studies will populate the greater
outcome list to be used at the Delphi stage, we believe
that this is not a limitation of our study, as outcomes
will not be weighed on the number of participants who
mention them.
Research efforts will take into account individual,
social and cultural differences. This will be crucial in
producing results which can help health professionals to
identify, not only the core outcomes as defined by the
participants themselves, but also, to devise and identify
potential measures to assess and identify whether these
outcomes are being achieved.
All studies will obtain local ethical approval prior to
study start. The Swiss study about patient and family de-
fined outcomes was given clearance by the local ethics
committee (KEK 2016–00896).
Participants
Patients The main target group for data collection is of
individuals who can be characterized as living their last
days of life (7 days before death). However, taking into
consideration the difficulties in recognising dying [46,
47], and the difficulties of obtaining patient consent at
this stage, within iLIVE, we aim to collect this data lon-
gitudinally with patients who have a life expectancy of 6
months or less and who will be followed up 1-month
after study inclusion. While some participants would not
be as close to living the last days of life as others, all par-
ticipant data will nonetheless be employed, and aspects
for potential comparisons, differences and similarities
between groups will be considered. Potential patients
should have the ability to provide informed consent (if
required for the specific type of study), be 18 years old
or older, communicate in the language in which the re-
search will be undertaken, and be able to tolerate the de-
mands of participation depending on the study format.
Family members The perspective of family members on
what outcomes are important, for them as individuals,
and for the dying family member in the last days of life
can be collected prospectively or retrospectively. Pro-
spective data within iLIVE will be collected from families
starting from a life expectancy of 6 months or less, 1
month after study inclusion, and about 3 months after
death. In studies where data is collected retrospectively,
bereaved family members will be invited to participate in
the study within 3 to 12months from the death of their
family member. While different time frames have been
used in bereavement studies, and a potential optimal
time frame has been found to vary between individuals
[48], we have selected 3–12months after death, because
this timeframe may be seen more positively by the stric-
ter ethics committees, while still being early enough to
facilitate recollection of what happened during the last
days/weeks of life of a dying family member. Participants
must be able to provide informed consent and must
speak fluently in any of the languages of the study. Pro-
spective studies will focus on the experiences as they are
occurring to family members before death.
Data collection
Data collection and sampling will be undertaken as de-
fined in each study protocol. In each of the participating
countries, particularly in those where a qualitative design
will be employed, data from patients and bereaved
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relatives is expected to be collected in parallel, in order
to enrich the data collection process.
Outcome data from all international studies will be
collated and added to the list of outcomes identified
through the systematic review of the literature. Any out-
come ambiguities will be resolved with the Leadership
group for COS development (composed by a smaller
group of clinicians and researchers involved in the stud-
ies, and lay people or their representatives).
Data analyses
Data will be analysed according to the specific methodo-
logical approach, e.g., qualitative methods for interview
data, while survey or Q-sort card data will be analysed
through descriptive statistical techniques, or a mix of
quantitative and qualitative methods, as will be the case
with the data collected prospectively through iLIVE. Ul-
timately, each individual project leader will define the
procedure, as long as they can provide the COS develop-
ment team results that can be incorporated into the out-
comes list and that have been developed following the
required local ethical requirements.
Identification of main outcomes
This stage of the COS development process aims to pro-
vide a greater understanding of the priorities and needs
of patients and families during the last days of life and
will shed light on whether patient and family priorities
for the last days of life are different from those currently
employed as outcome measures. The studies on the pa-
tient and family perspective will help identify a list of
outcomes of importance to each of these groups in the
last days of life.
Taking into account the intended heterogeneity of the
sample (differences in time to death, ages, genders, diag-
noses, and cultural backgrounds) the analyses will take
into account these potential subgroups to identify
whether differences may exist in the end of life prefer-
ences/outcomes of each group. Differences in outcomes
that are important for family members in contrast to
those of patients will also be noted, and if different, they
will justify the development of outcomes focused on the
patient, and outcomes focused on the family.
Stage 3: international Delphi study
The Delphi study has been prospectively authorised by
the Bernese Cantonal Ethical Commission with a declar-
ation of no objection, meaning that this part of the study
is exempted from further ethical review (req-2019-
00200). The potential long list of outcomes collated
through stages 1 and 2 of the study, along with demo-
graphic items, will form the basis of the Delphi survey.
Outcomes will be organised within domains. In order to
reduce bias on the importance of each outcome, all
outcomes will be presented in alphabetical order, per
greater domain and within each domain.
Participants
The four stakeholder groups of interest for the Delphi
study will be clinicians, researchers, family members,
and patient representatives. In stages 3 and 4 the inclu-
sion of patient participants will not be possible since
participants’ illnesses will be far too advanced to enable
them to comply with the demands of the Delphi study
or to attend the consensus meeting. One of the main
challenges of COS studies is to preserve the patient per-
spective throughout the Delphi study and the consensus
meeting, particularly when they are not able to partici-
pate actively. Therefore, in this study we will include a
patient representative group formed by people heavily
involved in providing non-professional support at the
end of life, such as volunteers. Palliative care volunteers
have close proximity to patients up to late stages of the
illness, including the moment of death, and therefore
can speak about their needs in a way that would be more
difficult for family members. Public involvement associa-
tions and organisations will be contacted to support this
task. In the countries where no formal volunteer services
exist, local patient representative organisations will be
asked to nominate suitable participants to represent the
views of patients.
While the specific number of participants per group
will not make a difference for analysis, since we will
present results per group, considering the importance of
each of the four stakeholder groups, we expect that all
participant groups have a similar number of participants.
To reduce attrition, measures such as acknowledging
participation of each individual in all publications will be
employed, as long as the individual agrees for their name
to be published.
According to COMET guidelines for the development
of COS, a sample size calculation for Delphi studies is
not required and is not dependent on statistical notions
such as power, as it is often one of convenience [39]. To
increase uptake and value of the COS, however, it is cru-
cial that the Delphi participants can be described as ex-
perts within their stakeholder groups. In addition,
ensuring representation from a variety of countries and
different demographic characteristics across and within
groups brings more value by making the COS more
internationally relevant and thus more generalisable.
Therefore, as a minimum, we will include participants
from the eleven countries participating in the cohort
study within the iLIVE project, ensuring international
heterogeneity and relevance. From each country we will
obtain a list of 10 potential participants per stakeholder
group. Taking into consideration that there are 4 stake-
holder groups, 40 individuals will be contacted per
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country, for a total of 440 potential participants. Equal
numbers per country, per stakeholder group will not be
a requirement, as long as the countries have similar
characteristics, e.g. similar global location, cultural and
spiritual characteristics such as religiosity. This means
that countries such as Argentina and New Zealand, for
example, should not be merged in the same group.
Should groups need to be merged, the decision will be
made by the COS Leadership group. In addition, outside
of the countries participating in iLIVE, which already
represent South America, Europe, and Oceania, we will
have representation from Portugal, India and Pakistan,
and through the contacts from the International Collab-
orative for Best Care for the Dying Person, we will ex-
tend the invitation to the different members, who
represent about 21 countries of different income levels
and regions. Other international associations will be
asked to support recruitment for the Delphi study, ac-
cording to need.
Clinicians Physicians, nurses and allied health profes-
sionals dealing with patients at the end of life, including
palliative care specialists, mobile care teams, community
nurses, general practitioners, but also those practising in
other settings where people die, such as the emergency
department, the intensive care unit, and aged care facil-
ities, etc., will be invited. Each of the countries will nom-
inate key people from their own countries, but also at an
international level, so as to ensure wider international
relevance of the COS.
Researchers Active researchers will be identified by
each of the participating COS development groups.
Similar to the selection criteria for clinicians, it is ex-
pected that this group is heterogeneous in terms of main
degree, years of practice, seniority, etc. These differences
will help ensure representativeness.
Patients Direct participation of patients will not be pos-
sible. With the specific timeframe of the study being
the last days and weeks of life, participants will not be
able to participate in the Delphi study. Therefore, their
voice will be heard in stages 3 and 4 through people
who have contact with patients during this time, and
who can speak for them without letting their own per-
sonal needs come in the way. We consider hospice and
palliative care volunteers to be an ideal group to voice
the needs of patients in the last week of life. Opposite to
family members, who can only speak from their individ-
ual experience, volunteers have generally wide experi-
ence with patients and can thus act as advocates for the
patient group as a whole.
Family members Family members from deceased pa-
tients will be identified through the centres associated
with project members of the iLIVE project. These in-
clude hospitals, hospices, and palliative care units. We
will include family members who already have experi-
enced the death of a significant other. Because we are fo-
cused on the last week of life, we do not want to ask
families when it is too early for them to imagine what
the needs in the last week of life will be like, nor closer
to the death of their significant other death, as that time
is intensely personal.
In order to facilitate participation of individuals with a
non-academic/non-scientific background, they will be
provided with definitions, explanations, and clear in-
structions through written means, and they will also be
given the details of a local contact person who can solve
any unanticipated issues, if any arise. All participants will
be initially contacted electronically and invited to par-
ticipate in the study. However, if the electronic format
was too difficult to implement with a particular stake-
holder group, printed versions of the Delphi question-
naire will be sent by post and reply paid envelopes will
be provided to them. Depending on the specific round,
participants will also receive prior results in this same
format. Their answers will later on be transcribed into
the DelphiManager system so that they can be com-
puted along with all other responses.
Delphi rounds
The DelphiManager system from the COMET initiative
will be employed to build, distribute, and manage the
Delphi surveys. The Delphi study will consist of at least
two rounds, with the final number of rounds determined
on whether consensus was reached according to pre-
specified criteria (see Fig. 2).
In Round 1, all preselected outcomes will be presented
in a list and each participant will be asked to rank each
one of them from 1 to 9, where 1 is the least important
and 9 is of highest importance. Following the scale from
the GRADE group [49], the lowest scores (1, 2, and 3)
will be considered as ‘not that important’, 4 to 6 will be
considered as ‘important but not critical’, and 7 to 9 will
be considered as ‘important and critical’. To determine
which items should be in the final list, the thresholds
suggested by the COMET group [38] will be employed:
per item, consensus to include an item will be when over
70% of the participants score the item between 7 to 9,
and less than 15% of the participants scored the same
item as 1 to 3. Consensus to exclude an item, on the
other hand, will be achieved when over 70% of the par-
ticipants have scored the item between 1 to 3, and less
than 15% of the participants score the same item be-
tween 7 to 9. Any uncertainties in establishing consensus
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will be discussed and resolved with the COS Leadership
Group.
Participants will be given 3 weeks to respond the sur-
vey and will receive a reminder at the beginning of the
second week. In this same round, participants will be
asked to nominate any outcomes which are relevant
from their perspective, but which were not included in
the initial list. This will facilitate inclusion of outcomes
that may be relevant but that we did not obtain in stages
1 and 2 of the study.
Round 2 and round 3 will include all items selected
through the consensus to include procedure, as well as
those where there was no consensus, and all new
items proposed by the participants (new items will
only be asked for in the first round, therefore no new
items will be added beyond Round 2). Items for
which consensus to exclude was reached, will be
omitted. In Round 2 and any subsequent rounds,
participants will be given the opportunity to see a
histogram displaying the distribution of scores given
by participants from each stakeholder group, along
with their own previous score, and will be able to re-
score each item if they wanted to.
Participants will receive four sets of results, one from
each of the stakeholder groups separately. This means
that each individual participant will see the scores given
by the clinician group, the researchers, the patients
(through representatives), and the family members. Next
to these would be their own previous score and they
would have the opportunity to change or reinstate their
score.
If after three rounds several items still remain without
consensus, the Delphi study will be terminated and the
outcomes where no consensus was found, will be pre-
sented at the consensus meeting. An effort will be made
to ensure a similar number of participants per group, so
Fig. 2 Delphi study flowchart
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as to not give more influence to a particular group.
When differences exist between stakeholder groups in
the final list of core outcomes, these differences will be
preserved and discussed during the consensus meeting.
That is, if there was no final consensus across the four
stakeholder groups, four sets of outcomes will be pre-
sented at the consensus meeting.
Study 4: face-to-face consensus meeting
In the development of a COS, the final step is a face-to-
face consensus meeting. The main outcome of the meet-
ing will be the definition, endorsement, and proposal of
the final core outcome set, including any potential do-
mains and subdomains. The Bernese Cantonal Ethical
Commission authorised the consensus meeting declaring
it exempt from further ethical review (req-2019-00200).
The consensus meeting is expected to take place as an
independent event, possibly within the context of an
international meeting dedicated to the discussion of end
of life outcomes and organised by the COS development
group. This way, before participants are shown the re-
sults of the Delphi, they can be socialised to different
perspectives on outcomes relevant at the end of life,
which may help them decide their votes. Participants for
the consensus meeting will be purposefully selected from
those participating in the Delphi study, to ensure repre-
sentativeness from the greater group. Because of fund-
ing, not all countries will be expected to have
representatives from the 4 stakeholder groups. From the
researcher and clinician groups, it is expected that at
least all countries are represented by one of each group
(20 participants), for the family and patient representa-
tives, at least half of this number will be expected (10
participants), and considering funding issues to cover
their travelling fees not all countries are expected to
have family or patient representatives present.
At the consensus meeting, all participants will be
present in the same room and will be shown all the con-
sensus to exclude items, as well as the results for the
items where consensus for inclusion was reached, and
those where no consensus was reached. To ensure that
participants are not coerced, or have to vote under peer
pressure for outcomes that they do not value, everyone
will vote anonymously through tablets or their smart-
phones. Differences between participants will be negoti-
ated and the final COS will be decided upon.
COS dissemination and implementation plan
Beyond the development of a COS, COS developers are
encouraged to devise strategies to improve the adoption
of the COS in the settings that it has been devised for
[39]. The COS for best care for the dying person is ex-
pected to have an impact in research and in clinical
practice, therefore, the strategies to be implemented will
address both contexts. Further to updating the COMET
registry on the status of the COS, the COS development
group will publish the final COS in a renowned palliative
care journal, as well as aim to present it at an inter-
national palliative care conference. In addition, an edi-
torial or commentary about the newly developed COS,
as well as its expected impact in reducing research waste
[26, 27] will be sought from a relevant palliative care
journal.
A periodical review of COS uptake will help measure
in which contexts and up to what extent the COS is be-
ing employed by clinicians and researchers. Through the
periodical review, a decision on whether the COS may
require an update to reflect newer trends or perspective
may also need to be made, thus leading to repeating
some stages of the COS development process.
Discussion
The COS produced at the end of this study will identify
what minimum outcomes should be employed in the
last days/weeks of life, both in research and in clinical
practice. A similar process to establish how to measure
the proposed outcomes will be implemented after the
development of the COS.
The development of core outcome sets is a healthcare
priority. Without a unifying outcome framework
through which the effectiveness of palliative care inter-
ventions can be compared across clinical trials in sys-
tematic reviews, research efforts will have little to no
impact. If consistently employed, a robust set of core
outcomes for the last days/weeks of life, defined by all
relevant stakeholders, will ultimately be translated into
best care for the dying person and their families. Patient
care will be improved by allowing clinicians to choose
effective and meaningful treatments, and the impact of
research will be significantly improved by measuring
generally agreed endpoints which can be compared be-
tween studies and in meta-analyses. The core outcome
sets are expected to become standards of quality of the
care provided to patients living the last days of life, and
will also be standards for comparisons between clinical
trials.
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